Finerenone: Who should prescribe it for CKD? The physician associate’s perspective
2024

Finerenone: Who should prescribe it for CKD?

Sample size: 13026 publication 10 minutes Evidence: high

Author Information

Author(s): Becky M. Ness, Heidi Webb

Primary Institution: Mayo Clinic College of Medicine

Hypothesis

How can physician associates be empowered to prescribe finerenone for chronic kidney disease (CKD) patients?

Conclusion

Empowering physician associates in the management of diabetic kidney disease can improve patient outcomes and reduce the burden of chronic kidney disease.

Supporting Evidence

  • Finerenone reduced cardiovascular outcomes by 14% and kidney outcomes by 23% compared to placebo.
  • Physician associates can monitor kidney function and encourage patient self-management.
  • Early detection and management of CKD can prevent kidney failure and cardiovascular events.

Takeaway

This study shows that physician associates can help patients with kidney disease by prescribing important medications and monitoring their health.

Methodology

The study reviews existing literature and clinical trials related to finerenone and its effects on CKD.

Potential Biases

Potential bias in prescribing patterns among primary care providers versus specialists.

Limitations

The study may not account for all variables affecting CKD management in diverse populations.

Participant Demographics

Adults with type 2 diabetes and chronic kidney disease.

Statistical Information

P-Value

p<0.05

Confidence Interval

0.73–0.93

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1007/s40620-024-02015-5

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication